Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Meglitinides Archives
Print | Email | Share | Comments (2)

ACP Guidelines Say Metformin Is the Best Starter Drug for Type 2s


Mar 1, 2012

The latest clinical guidelines for treating type 2 diabetes from the American College of Physicians (ACP) indicate that when diet, exercise, and weight loss fail to control blood sugar levels in early type 2 patients, physicians should prescribe metformin as the first drug therapy.

The ACP recommends that metformin be prescribed initially as a stand-alone monotherapy. As the disease progresses and metformin's initial efficacy begins to fade, doctors can add a second drug.

To develop its recommendations, the ACP examined 44 years of data on the performance of all FDA-approved oral medications for type 2s, from 1966 through early 2010. The drug types reviewed included metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, and GLP-1 receptor antagonists.

The ACP discovered that while most of the drugs have similar effects in reducing blood sugar levels, metformin is the most effective in doing so, whether used alone or in combination. The ACP also found that metformin helps reduce body weight and improve cholesterol counts.

The study reinforces what has become a common practice among healthcare professionals who deal with type 2 diabetes. Metformin, first developed in the 1970s, has become the preferred first medication prescribed for patients with early-stage type 2. It has also become a common therapy for prediabetes patients and people with metabolic syndrome who are attempting to stave off type 2 diabetes.

The ACP noted that there was insufficient evidence to discern any difference in the efficacy of type 2 drugs among adults based on age, sex, or ethnicity.

 


Categories: ACP, American College of Physicians, Blood Sugar Levels, Diabetes, Diabetes, DPP-4 Inhibitors, Early-Stage Type 2, FDA, GLP-1 Receptor Antagonists, Meglitinides, Metformin, Oral Medications, Sulfonylureas, Thiazolidinediones, Type 2 Diabetes, Type 2 Issues, Type 2 Patients



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 2 comments - Mar 1, 2012

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.